Outcome of Board Meeting held on June 29, 2026
As filed · Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on June 29, 2026.
What happened
FactSenores Pharmaceuticals Limited's Board of Directors approved a proposed variation in the utilization of ₹ 1000.16 million from the unutilized portion of the Initial Public Offer proceeds, subject to shareholder approval through a Postal Ballot. The decision was made during a meeting held on June 29, 2026. The company has also made this information available on its website.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedEBITDA margins stood at almost 30%, improving by 810 bps Y-o-Y.
Consolidated EBITDA for Q1 of FY27 stood at INR54 crores, growing by a robust 87% on a Y-o-Y basis.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Based on the current business outlook and execution visibility, we expect the revenue growth of approximately (management committed by FY27)
- FY’27. So, next year, FY’27, we feel that margin when we get to about 18%, 20% to 22% kind of a number should (management committed by FY27)
Evidence
- Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on June 29, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%